Ebola took the world by surprise leading to a huge loss of human lives in the Western Africa plateau. With no steady treatment available for the Ebola virus, pharmaceutical companies are trying every bit to devise a medical treatment for the disease. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Sarepta Therapeutics Inc (NASDAQ:SRPT) are the current market leaders in developing a vaccine for Ebola virus.
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) is likely to be the first company to release certified treatment for Ebola and its shares closed at $24.99 after the first identified Ebola victim in the United States. Texas Health Presbyterian Hospital of Dallas is keeping the patient in isolation and the suspicion rose after reviewing the symptoms and recent travel history of the individual. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) received approval for its Ebola treatment named TKM-Ebola from both FDA and Health Canada and the same is to be used in the current Ebola affected western African countries.
All the major companies with significant research in Ebola witnessed a rise in their shares including BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), which is engaged in developing an Ebola therapy for affected populace. BioCryst witnessed 3.78% increase in its share prices after the first US Ebola-victim identification. The company would conduct trials for its drug, BCX4430, in alliance with the National Institute of Allergy and Infectious Disease.
The shares for Sarepta Therapeutics Inc (NASDAQ:SRPT) rose 3.70% at $21.88 towards the end of the trading session and the company is working to create an anti-drug for Ebola. Chris Garabedian, CEO of Sarepta Therapeutics Inc (NASDAQ:SRPT), announced that the company has up to 100 doses for the treatment of Ebola patients.
This article has been written by Prakash Pandey.